122 related articles for article (PubMed ID: 38307565)
1. Effects of Extended Fixation on Advanced Gastric Cancer HER2 Status Assessment Using IHC and FISH.
Kondo J; Yoshino S; Iida M; Takeda S; Nakashima C; Watanabe Y; Nishiyama M; Tokumitsu Y; Shindo Y; Nishimura T; Suzuki N; Hoshii Y; Itoh H; Nagano H
Anticancer Res; 2024 Feb; 44(2):621-630. PubMed ID: 38307565
[TBL] [Abstract][Full Text] [Related]
2. Importance of formalin fixing conditions for HER2 testing in gastric cancer: immunohistochemical staining and fluorescence in situ hybridization.
Yamashita-Kashima Y; Shu S; Yorozu K; Hashizume K; Moriya Y; Fujimoto-Ouchi K; Harada N
Gastric Cancer; 2014 Oct; 17(4):638-47. PubMed ID: 24414131
[TBL] [Abstract][Full Text] [Related]
3. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma.
Yoshida H; Yamamoto N; Taniguchi H; Oda I; Katai H; Kushima R; Tsuda H
Virchows Arch; 2014 Aug; 465(2):145-54. PubMed ID: 24889042
[TBL] [Abstract][Full Text] [Related]
4. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
[TBL] [Abstract][Full Text] [Related]
5. Human epidermal growth factor receptor 2 amplification detection by droplet digital polymerase chain reaction in formalin-fixed paraffin-embedded breast and gastric cancer samples.
Wang X; Wu Y; Song X; Sun C; Wu C; Feng H
J Cancer Res Ther; 2017; 13(4):730-734. PubMed ID: 28901323
[TBL] [Abstract][Full Text] [Related]
6. Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization.
Kanayama K; Imai H; Yoneda M; Hirokawa YS; Shiraishi T
Cancer Sci; 2016 Apr; 107(4):536-42. PubMed ID: 26752196
[TBL] [Abstract][Full Text] [Related]
7. Concordance of HER2 status tested by IHC and FISH in biopsy and surgical resection specimens and comparison with clinicopathological features in gastric carcinoma.
Nergiz D; Alikanoğlu AS; Süren D; Gömceli İ; Öztürk B
Indian J Pathol Microbiol; 2022; 65(2):321-327. PubMed ID: 35435366
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).
Matsusaka S; Nashimoto A; Nishikawa K; Miki A; Miwa H; Yamaguchi K; Yoshikawa T; Ochiai A; Morita S; Sano T; Kodera Y; Kakeji Y; Sakamoto J; Saji S; Yoshida K
Gastric Cancer; 2016 Jul; 19(3):839-51. PubMed ID: 26265390
[TBL] [Abstract][Full Text] [Related]
9. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
[TBL] [Abstract][Full Text] [Related]
10. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
[TBL] [Abstract][Full Text] [Related]
11. [Delay in formalin fixation and HER2 testing in gastric cancer].
Zeng L; Huang J; Ma Y; Liu Y; Wei Y; Zheng Q; Ye H
Zhonghua Bing Li Xue Za Zhi; 2014 Jul; 43(7):468-72. PubMed ID: 25327797
[TBL] [Abstract][Full Text] [Related]
12. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
13. HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance.
Huang SC; Ng KF; Lee SE; Chen KH; Yeh TS; Chen TC
Gastric Cancer; 2016 Jan; 19(1):176-82. PubMed ID: 25512144
[TBL] [Abstract][Full Text] [Related]
14. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
Kiyose S; Igarashi H; Nagura K; Kamo T; Kawane K; Mori H; Ozawa T; Maeda M; Konno K; Hoshino H; Konno H; Ogura H; Shinmura K; Hattori N; Sugimura H
Pathol Int; 2012 Nov; 62(11):728-34. PubMed ID: 23121603
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the types of candidate reference samples for quality control of human epidermal growth factor receptor 2 status detection.
Li Y; Zhang R; Han Y; Lu T; Ding J; Zhang K; Lin G; Xie J; Li J
Diagn Pathol; 2016 Sep; 11(1):85. PubMed ID: 27613595
[TBL] [Abstract][Full Text] [Related]
16. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).
Boers JE; Meeuwissen H; Methorst N
Histopathology; 2011 Feb; 58(3):383-94. PubMed ID: 21323962
[TBL] [Abstract][Full Text] [Related]
17. Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer.
Stocker A; Trojan A; Elfgen C; Hilbers ML; Moskovszky L; Varga Z
Breast Cancer Res Treat; 2020 Sep; 183(2):311-319. PubMed ID: 32638236
[TBL] [Abstract][Full Text] [Related]
18. A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity.
Nishida Y; Kuwata T; Nitta H; Dennis E; Aizawa M; Kinoshita T; Ohtsu A; Ochiai A
Gastric Cancer; 2015 Jul; 18(3):458-66. PubMed ID: 24917219
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
20. HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance.
Sheng WQ; Huang D; Ying JM; Lu N; Wu HM; Liu YH; Liu JP; Bu H; Zhou XY; Du X
Ann Oncol; 2013 Sep; 24(9):2360-4. PubMed ID: 23788757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]